Printer Friendly

NEW DRUG SHOWS PROMISE AGAINST FATAL LUNG DISEASE, HEART ATTACKS; RESEARCHERS REPORT PROGRESS IN FIGHT AGAINST ARDS, AMI

NEW DRUG SHOWS PROMISE AGAINST FATAL LUNG DISEASE, HEART ATTACKS;
 RESEARCHERS REPORT PROGRESS IN FIGHT AGAINST ARDS, AMI
 Results of the first two preclinical studies demonstrating the effectiveness of a new liposome-encapsulated prostaglandin E1 (TLC C 53) in treating heart attacks, or acute myocardial infarctions (AMI) and Adult Respiratory Distress Syndrome (ARDS) will be presented on Friday, May 1, at 7:30 p.m., Exhibit Hall B and Sunday, May 3, at 2:30 p.m. Room 321, respectively, during the annual meeting of the American Federation for Clinical Research and its sister societies at the Baltimore Convention Center, Baltimore, Md.
 The press office will hold a briefing on Saturday, May 2, at 2:30 p.m. in Room 311.
 In the AMI study, investigators examined the effect TLC C-53 had on an animal model of a simulated heart attack and will report a 50 percent reduction in the amount of heart damage, compared to control. The experiments were carried out at the University of Texas Medical School (UTMS) at Houston and won for the investigators the federation's prestigious Henry Christian Award for Excellence.
 The ARDS study compared the effectiveness of TLC C-53 to free prostoglandin E1 (PGE1) in decreasing the neutrophil activation and migration that appear to cause ARDS and found that TLC C-53 dramatically decreased the amount of lung injury. There currently are no effective drugs for this condition, which kills more than 100,000 people each year. Investigators from the Webb-Waring Lung Institute of the University of Colorado (UC) collaborated on the study.
 George Li, M.D., instructor of medicine, division of cardiology, UTMC, will present the results of the AMI study. The principal investigator is Richard W. Smalling, M.D., Ph.D., professor of medicine, division of cardiology, UTMC.
 Jonathan A. Leff, M.D., an investigator at Webb-Waring and assistant professor of medicine at UC, will deliver the ARDS-experiment findings. The co-investigator is John Repine, M.D., director of Webb Waring and professor of medicine at UC.
 TLC C-53 is under development by The Liposome Co. Inc., Princeton, N.J. The company expects to file an IND (Investigation New Drug) application with the U.S. Food and Drug Administration and begin clinical trials later this year.
 CONTACT: Steve Marks, 312-988-2348 (May 1-3, 301-727-2222), for The Liposome Co.
 -0- 4/30/92


CO: Liposome Co. ST: Maryland IN: MTC SU:

SH -- NY082 -- 5038 04/30/92 14:34 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1992
Words:402
Previous Article:NATURAL EARTH TECHNOLOGIES ADDS TO GARDEN THUNDER PRODUCT LINE
Next Article:UNITED AIRLINES NAMES SPEICHER SENIOR VICE PRESIDENT-HAWAII


Related Articles
LEADING RESEARCHERS PRESENT PRECLINICAL RESULTS WITH THE LIPOSOME COMPANY'S TCL C-53
LIPOSOME COMPANY'S FOURTH DRUG ENTERS CLINICAL TRIALS; BEING DEVELOPED TO TREAT OFT-FATAL LUNG DISEASE
LIPOSOMAL PROSTAGLANDIN IMPROVES OUTCOMES IN ARDS PATIENTS
Aurora Biosciences Announces Drug Discovery and Development Collaboration With the Cystic Fibrosis Foundation.
Advanced Life Sciences Files Investigational New Drug Application for Anti- Inflammatory Agent.
Biomedicine. (Science News of the year: the weekly newsmagazine of science).
Acetaminophen May Be the Pain Reliever of Choice for Millions On Cardioprotective Aspirin Therapy; New Study Shows Popular Over-the-Counter...
Biomedicine.
CRYPTOME GETS OPTION FOR ANTI-INFLAMMATORY DRUG LICENSE.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters